aid: acelot-inc
name: Acelot, Inc.
description: >-
  Acelot, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco,
  California, developing first-in-class small-molecule therapies for neurodegenerative diseases with
  high unmet need. Its lead candidate, ACE-2223, is designed to target misfolded and aggregated
  TDP-43 and restore the protein's healthy form and function, addressing pathology central to
  amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Acelot's
  discovery work is powered by Resolute, an internal integrated drug-discovery platform combining
  AI-driven computational chemistry with structural and biological insight to drug historically
  intractable protein targets. Acelot publishes no public API, developer portal, SDK or
  machine-readable specification; its four public GitHub repositories are forks of third-party
  cheminformatics tooling.
image: https://static1.squarespace.com/static/6721bd430e24a6572ea4152a/t/6732691e70799e3f6a4e8b71/1731356958733/Acelot-Website-LogoKnockout-111124-v01.png?format=1500w
url: https://raw.githubusercontent.com/api-evangelist/acelot-inc/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-09-06'
modified: '2026-09-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Life Sciences
- Neurodegenerative Disease
- Artificial Intelligence
- Computational Chemistry
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.acelot.com/
- type: Blog
  url: https://www.acelot.com/news
- type: BlogRSS
  url: https://www.acelot.com/news?format=rss
- type: GitHubOrganization
  url: https://github.com/acelot-inc
- type: LinkedIn
  url: https://www.linkedin.com/company/acelot-inc./
- type: x-Publications
  url: https://www.acelot.com/publications
- type: x-Team
  url: https://www.acelot.com/our-team
- type: DomainSecurity
  url: security/acelot-inc-domain-security.yml
- type: LLMsTxt
  url: llms/acelot-inc-llms.txt
x-enrichment:
  date: '2026-09-06'
  status: minimal
  artifacts_added: 3
  pass: local-v3
x-coverage:
  state: none
  reason: no-developer-program
  detail: >-
    Acelot is a clinical-stage biopharmaceutical company whose product is a small-molecule
    therapeutic (ACE-2223), and its Resolute AI drug-discovery platform is described by the
    company as employed in-house only — acelot.com is a five-page Squarespace marketing site with
    no developer, docs or API section, and every contract-discovery path returned 404 on both
    acelot.com and www.acelot.com.
  evidence:
  - url: https://www.acelot.com/pipeline-and-platform
    status: 200
  - url: https://www.acelot.com/openapi.json
    status: 404
  - url: https://www.acelot.com/swagger.json
    status: 404
  - url: https://www.acelot.com/api-docs
    status: 404
  - url: https://www.acelot.com/graphql
    status: 404
  - url: https://www.acelot.com/mcp
    status: 404
  - url: https://www.acelot.com/llms.txt
    status: 404
  - url: https://www.acelot.com/.well-known/agent-card.json
    status: 404
  - url: https://www.acelot.com/.well-known/api-catalog
    status: 404
  - url: https://github.com/acelot-inc
    status: 200
  checked: '2026-09-06'